Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.

[1]  T. Nakajima,et al.  Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter , 2018, Cancer science.

[2]  J. Mazières,et al.  PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. , 2018, Lung cancer.

[3]  Y. Maehara,et al.  PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. , 2018, Lung cancer.

[4]  G. Kallergi,et al.  Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer , 2018, Therapeutic advances in medical oncology.

[5]  Y. Koh,et al.  Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients , 2017, PloS one.

[6]  F. Hirsch,et al.  PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[8]  C. Paweletz,et al.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Cortesi,et al.  Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab , 2016, Scientific Reports.

[10]  T. Nakajima,et al.  Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure , 2016, Cancer science.

[11]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[12]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[13]  Y. Nakanishi,et al.  Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Akira Ono,et al.  Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System , 2013, PloS one.

[15]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[16]  Nobuyuki Yamamoto,et al.  Microcavity array system for size-based enrichment of circulating tumor cells from the blood of patients with small-cell lung cancer. , 2013, Analytical chemistry.

[17]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[18]  T. Fehm,et al.  HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial , 2010, Breast Cancer Research and Treatment.

[19]  A. Gemma,et al.  F1000 highlights , 2010 .

[20]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[21]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[22]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[23]  C. Marquette,et al.  Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.